Biotechnology is a topic of considerable diversity and implications for the future, if not the very philosophy, of health care. In many respects, biotechnology differs markedly from traditional sources of new therapeutic agents. Biotechnology is viewed as encompassing three major areas: genetic engineering, molecular synthesis, and drug delivery systems. Each of these a as is an important source of pharmacologic agents. The implications for biotechnology for the drug development process are examined with particular reference to opportunities for the statistician or bio-statistician to contribute
JacksonDASymonsRHBergP.(1972). Biochemical method for inserting new genetic information into DNA of simian virus 40: Circular SV40 DNA molecules containing lambda phage genes and the galactose operon on Escherichia coli.Proc Natl Acad Sci USA.1972;69:2904–2909.
2.
GuralnikDB, ed. Webster's new world dictionary. New York: Simon & Schuster; 1980:p 143.
3.
KorwekELFDA regulation of biotechnology as a new method of manufacture. Food Drug Cosmetic Law J.1982;37:289–309.
4.
WroblewskiJ.Genetic engineering: Widening drug horizons. Drug Topics. 1982;126(Feb 1):32–34.
LobbanPEKaiserAD(1973). Enzymatic end-to-end joining of DNA molecules. J Mol Biol. 1973;78:453–471.
7.
MorrowJFCohenSNChangACYBoyerHWGoodmanHMHellingRBReplication and transcription of eukaryotic DNA in Escherichia coli.Proc Nat Acad Sci USA.1974;71:1743–1747.
LeithJ.The livestock industry's genetic revolution. Business Week. 1982;June 21:124–132.
10.
VerstraeteMBrowerRWCollenDDunningAJLubsenJMichelPLSchoferJVanhaeckeJvan de WerfFBleifeldWCharbonnierBde BonoDPLennaneRJMatheyDGRaynaudPVahanianAvan de KleyGAvon EssenRDouble-blind randomized trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet. 1985; Nov 2:965–969.
11.
WhiteJPHigh-tech drugs to burst on pharmacy scene. Drug Topics. 1986;130(June 2):38–39, 42, 44.
12.
Synthetic membranes: The next technology to watch. Business Week. 1984;Nov 12:154.
AndersonWFHuman gene therapy for adenosine deaminase deficiency to be submitted for FDA review; NIH's RAC subcommittee gets first draft proposal for clinical trials. F-D-C Reports. 1987;49(May 4):4–5.
15.
GussinRZRecent developments in biotechnology: The influence on drug development. Drug Inf J.1986;20:115–119.
16.
BrodieDCSmithWEImplications of new technology for pharmacy education and practice. Am J Hosp Pharm. 1985;42:81–95.
17.
RundellJORegulatory evolution and the biotechnology industryPharm Manuf. 1984; 59(Nov):33–35, 59.
18.
PickupJ.Human insulin. Br Med J.1986;292: 155–157.
19.
LeeREMonoclonal antibodies in the treatment of disease: Moving from mouse molecules to human. Can Med Assoc J.1986;134:21–23.
20.
SpaldingBJBiotech's new-wave biologicals. Chemical Week. 1985;137(Dec 18):26–29.
CheckWANew drugs and drug-delivery systems in the year 2000. Am J Hosp Pharm. 1984;41:1536–1547.
24.
WeckerMTGravesDAAmselLPHinsvarkONRotenbergKSInfluence of a standard meal on the absorption of controlled-release pseudophedrine capsules. J Pharm Sci.1987;76:29–31.
25.
ChengKTSeltzerSEAdamsDFBlauM.The production and evaluation of contrast-carrying liposomes made with an automatic high-pressure system. Invest Radiol. 1987;22:47–55.
TrunehAMachyPHoranPKAntibody-bearing liposomes as multicolor immunofluorescence markers for flow cytometry and imaging. J Immunol Methods. 1987;100:59–71.
28.
Orthoclone OKT-3 four year post-marketing surveillance.F-D-C Reports. 1986;48(Oct 13):T&G-2.
29.
SalsburgDSUse of statistics when examining lifetime studies in rodents to detect carcinogenicity. J Toxicol Environ Health. 1977;3:611–628.
30.
HasemanJKResponse to “Use of statistics when examining lifetime studies in rodents to detect carcinogenicity.”J Toxicol Environ Health. 1977;3:633–636.
31.
FearsTRTaroneREResponse to “Use of statistics when examining lifetime studies in rodents to detect carcinogenicity.”J Toxicol Environ Health. 1977;3:629–632.
32.
Anon. Recombinant DNA markets may exceed $3 billion by 1981. Am Pharm. 1980;NS21(Feb): 18.
